Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 8 years of Other Non-Current Liabilities data on record, last reported at $197000.0 in Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities changed 0.0% to $197000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $197000.0, a 0.0% change, with the full-year FY2025 number at $197000.0, changed 0.0% from a year prior.
  • Other Non-Current Liabilities reached $197000.0 in Q1 2026 per FULC's latest filing, roughly flat from $197000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for FULC hit a ceiling of $447000.0 in Q2 2023 and a floor of $197000.0 in Q2 2022.
  • A 5-year average of $220312.5 and a median of $197000.0 in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 126.9% in 2023, then crashed 55.93% in 2024.
  • Tracing FULC's Other Non-Current Liabilities over 5 years: stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then changed by 0.0% to $197000.0 in 2024, then changed by 0.0% to $197000.0 in 2025, then changed by 0.0% to $197000.0 in 2026.
  • Business Quant data shows Other Non-Current Liabilities for FULC at $197000.0 in Q1 2026, $197000.0 in Q4 2025, and $197000.0 in Q3 2025.